33 / 62
ORR and DOR
a
a
Per local investigator.
b
95% CI, 10.0–18.3%.
c
12.4–21.3%
0
5
10
15
20
Nivolumab Chemotherapy
ORR (%)
39/284
n/N:
47/285
Nivolumab Chemotherapy
CR
PR
13.7
b
16.5
c
13.4
16.1
0.4
0.4
ORR
33
Nivolumab
Chemotherapy
Nivolumab
(n = 39)
Chemotherapy
(n = 47)
Median DOR
8.3
4.5
(95% CI), mo
(7.0–12.6)
(4.1–5.8)
9
2
39
47
35
34
26
14
17
9
14
4
12
3
7
1
5
0
2
0
1
0
0
0
Patients in response (%)
100
80
60
40
20
0
0 3 6 9 12 15 18 21 24 27 30 33
Months
No. at risk
Nivolumab
Chemo